S&P 500   3,739.54 (-2.86%)
DOW   30,276.42 (-2.14%)
QQQ   319.71 (-2.70%)
AAPL   142.01 (-0.80%)
MSFT   231.83 (-0.22%)
FB   271.00 (-3.92%)
GOOGL   1,800.15 (-5.65%)
AMZN   3,233.50 (-2.78%)
TSLA   870.29 (-1.45%)
NVDA   514.75 (-4.22%)
BABA   261.17 (-1.79%)
CGC   37.71 (+6.17%)
GE   10.88 (-3.63%)
MU   74.65 (-6.11%)
AMD   88.90 (-6.13%)
NIO   56.96 (-5.55%)
T   29.12 (-2.12%)
F   10.78 (-3.66%)
ACB   11.28 (+5.72%)
BA   193.36 (-4.31%)
DIS   163.52 (-3.56%)
NFLX   532.43 (-5.25%)
GILD   65.60 (-1.65%)
S&P 500   3,739.54 (-2.86%)
DOW   30,276.42 (-2.14%)
QQQ   319.71 (-2.70%)
AAPL   142.01 (-0.80%)
MSFT   231.83 (-0.22%)
FB   271.00 (-3.92%)
GOOGL   1,800.15 (-5.65%)
AMZN   3,233.50 (-2.78%)
TSLA   870.29 (-1.45%)
NVDA   514.75 (-4.22%)
BABA   261.17 (-1.79%)
CGC   37.71 (+6.17%)
GE   10.88 (-3.63%)
MU   74.65 (-6.11%)
AMD   88.90 (-6.13%)
NIO   56.96 (-5.55%)
T   29.12 (-2.12%)
F   10.78 (-3.66%)
ACB   11.28 (+5.72%)
BA   193.36 (-4.31%)
DIS   163.52 (-3.56%)
NFLX   532.43 (-5.25%)
GILD   65.60 (-1.65%)
S&P 500   3,739.54 (-2.86%)
DOW   30,276.42 (-2.14%)
QQQ   319.71 (-2.70%)
AAPL   142.01 (-0.80%)
MSFT   231.83 (-0.22%)
FB   271.00 (-3.92%)
GOOGL   1,800.15 (-5.65%)
AMZN   3,233.50 (-2.78%)
TSLA   870.29 (-1.45%)
NVDA   514.75 (-4.22%)
BABA   261.17 (-1.79%)
CGC   37.71 (+6.17%)
GE   10.88 (-3.63%)
MU   74.65 (-6.11%)
AMD   88.90 (-6.13%)
NIO   56.96 (-5.55%)
T   29.12 (-2.12%)
F   10.78 (-3.66%)
ACB   11.28 (+5.72%)
BA   193.36 (-4.31%)
DIS   163.52 (-3.56%)
NFLX   532.43 (-5.25%)
GILD   65.60 (-1.65%)
S&P 500   3,739.54 (-2.86%)
DOW   30,276.42 (-2.14%)
QQQ   319.71 (-2.70%)
AAPL   142.01 (-0.80%)
MSFT   231.83 (-0.22%)
FB   271.00 (-3.92%)
GOOGL   1,800.15 (-5.65%)
AMZN   3,233.50 (-2.78%)
TSLA   870.29 (-1.45%)
NVDA   514.75 (-4.22%)
BABA   261.17 (-1.79%)
CGC   37.71 (+6.17%)
GE   10.88 (-3.63%)
MU   74.65 (-6.11%)
AMD   88.90 (-6.13%)
NIO   56.96 (-5.55%)
T   29.12 (-2.12%)
F   10.78 (-3.66%)
ACB   11.28 (+5.72%)
BA   193.36 (-4.31%)
DIS   163.52 (-3.56%)
NFLX   532.43 (-5.25%)
GILD   65.60 (-1.65%)
Log in
OTCMKTS:CRLBF

Cresco Labs Stock Forecast, Price & News

$12.37
-1.21 (-8.91 %)
(As of 01/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.30
Now: $12.37▼
$13.51
50-Day Range
$9.87
MA: $11.20▼
$14.20
52-Week Range
$1.94
Now: $12.37▼
$14.38
Volume1.94 million shs
Average Volume1.55 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells medical cannabis and medical cannabis products in the United States. It offers cannabis in flowers, live concentrates, and liquid live resins under the Cresco and Reserve brands; soft gels, tinctures, and lotions under the Remedi brand; gummies, fruit chews, hard sweets, and chocolates under the Mindy's brand; and vape pens, popcorn, shake, pre-rolls, and shorties under High supply brand. It operates 22 dispensaries in Illinois, Pennsylvania, Ohio, California, Nevada, Arizona, Massachusetts, and New York. The company is headquartered in Chicago, Illinois.
Cresco Labs logo

MarketRank™

Overall MarketRank™

1.07 out of 5 stars

Medical Sector

940th out of 1,925 stocks

Drug Manufacturers - Specialty & Generic Industry

17th out of 61 stocks

Analyst Opinion: 2.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CRLBF
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.crescolabs.com
Phone312-929-0993
Employees2,000
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable
$12.37
-1.21 (-8.91 %)
(As of 01/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRLBF News and Ratings via Email

Sign-up to receive the latest news and ratings for CRLBF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cresco Labs (OTCMKTS:CRLBF) Frequently Asked Questions

How has Cresco Labs' stock been impacted by Coronavirus?

Cresco Labs' stock was trading at $3.34 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CRLBF shares have increased by 270.4% and is now trading at $12.37.
View which stocks have been most impacted by COVID-19.

Is Cresco Labs a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cresco Labs in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cresco Labs stock.
View analyst ratings for Cresco Labs or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Cresco Labs?

Wall Street analysts have given Cresco Labs a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cresco Labs wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for CRLBF?

7 brokerages have issued 12 month target prices for Cresco Labs' shares. Their forecasts range from $4.20 to $24.00. On average, they anticipate Cresco Labs' stock price to reach $14.96 in the next twelve months. This suggests a possible upside of 20.9% from the stock's current price.
View analysts' price targets for Cresco Labs or view Wall Street analyst' top-rated stocks.

Who are some of Cresco Labs' key competitors?

Some companies that are related to Cresco Labs include (THCX.V) (THCX), 31444 (GLH), 438280 (ACG), 815446 (HC), Abacus Health Products (ABAHF), Acreage (ACRGF), Althea Group Holdings Limited (AGH.AX) (AGH), Applied Biosciences (APPB), AusCann Group Holdings Ltd (AC8.AX) (AC8), Ayr Strategies (AYRSF), Bio-Rad Laboratories (BIO), Blueberries Medical (BBM), Can B (CANB), Cannara Biotech (LOVE) and CannPal Animal Therapeutics Limited (CP1.AX) (CP1).
View all of CRLBF's competitors.

Who are Cresco Labs' key executives?

Cresco Labs' management team includes the following people:
  • Mr. Charles Bachtell, Co-Founder, CEO & Director (Age 42, Pay $663.7k)
  • Mr. Kenneth Edward Amann, Advisor (Age 49, Pay $378.3k)
  • Mr. Thomas J. Manning, Exec. Chairman (Age 64)
  • Mr. Dominic Anthony Sergi, Co-Founder & Independent Director (Age 37)
  • Mr. Robert M. Sampson, Co-Founder & Director (Age 46)
  • Mr. Dennis M. Olis, Chief Financial Officer (Age 57)
  • Mr. David Ellis, Chief Operating Officer (Age 38)
  • Ms. Brenna Albert CPA, Sr. VP & Controller of Accounting, Treasury & Tax
  • Mr. Mo Dastagir, Chief Information Officer (Age 43)
  • Mr. John Schetz, Gen. Counsel (Age 44)

What is Cresco Labs' stock symbol?

Cresco Labs trades on the OTCMKTS under the ticker symbol "CRLBF."

How do I buy shares of Cresco Labs?

Shares of CRLBF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cresco Labs' stock price today?

One share of CRLBF stock can currently be purchased for approximately $12.37.

What is Cresco Labs' official website?

The official website for Cresco Labs is www.crescolabs.com.

How can I contact Cresco Labs?

The company can be reached via phone at 312-929-0993.

This page was last updated on 1/27/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.